Aytu BioPharma (NASDAQ:AYTU) Stock Price Breaks Below Fifty Day Moving Average – What’s Next?

Aytu BioPharma Inc. (NASDAQ:AYTU) shares crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $2.15 and traded as low as $1.96. Aytu BioPharma shares last traded at $1.98, with a volume of 25,716 shares traded.

Analyst Ratings Changes

AYTU has been the subject of several recent research reports. Citigroup reissued a “positive” rating on shares of Aytu BioPharma in a research report on Tuesday, September 22nd. Zacks Research lowered shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a report on Monday, October 5th. Finally, Weiss Ratings lowered shares of Aytu BioPharma from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, October 6th. Two analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Aytu BioPharma has a consensus rating of “Hold” and a consensus price target of $14.50.

Aytu BioPharma Price Performance

The stock has a market capitalization of $21.52 million, a price-to-earnings ratio of -1.19 and a beta of 0.17. The business’s 50 day simple moving average is $2.15 and its 200-day simple moving average is $2.24. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.00 and a current ratio of 1.13.

Hedge Funds Weigh In On Aytu BioPharma

Large investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Aytu BioPharma during the second quarter worth about $49,000. Persistent Asset Partners Ltd purchased a new stake in shares of Aytu BioPharma during the second quarter worth $82,000. Dimensional Fund Advisors LP increased its holdings in Aytu BioPharma by 23.3% in the first quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock worth $119,000 after buying an additional 8,222 shares during the last quarter. Arete Wealth Advisors LLC bought a new position in shares of Aytu BioPharma during the 1st quarter valued at $135,000. Finally, Crown Advisors Management Inc. bought a new position in Aytu BioPharma during the second quarter valued at about $430,000. Institutional investors and hedge funds own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on developing and commercializing prescription medicines for pediatric and primary-care markets. The company’s portfolio includes treatments for attention-deficit/hyperactivity disorder (ADHD), along with products addressing allergies, respiratory conditions, and other common health needs.

Aytu’s ADHD portfolio has included orally disintegrating and liquid formulations designed for children and adolescents, such as Adzenys XR-ODT, Cotempla XR-ODT, and Dyanavel XR.